19 November 2015 in Chemical Communications
The split aptasensor for highly sensitive and specific detection of tumor cells based on FRET.
1 June 2017 in Chinese Chemical Letters
30 January 2020 in Journal of Thrombosis and Haemostasis
Background & Aims Patients with cirrhosis have a rebalanced hemostasis, often with normal or elevated thrombin‐generating (TG) capacity in plasma. Whole blood (WB) TG allows faster determination and, importantly, includes the influence of all circulating blood cells. We aimed to study the TG profile of patients with cirrhosis in WB and in platelet poor plasma. Methods TG in WB and plasma were assessed with a near‐patient WB‐TG assay and the Calibrated Automated Thrombinography, respectively. TG assays were tested in presence and absence of thrombomodulin. Conventional coagulation tests were also performed. Results Thirty‐four patients with cirrhosis and twenty‐two controls were analyzed. Compared with controls, patients had substantially deranged results in conventional coagulation tests. Comparable WB‐TG capacity (endogenous thrombin potential until peak, ETPp) but significantly lower peak thrombin were found in patients, and these results persisted when thrombomodulin was present. TG of the patients was more resistant to thrombomodulin than controls in both WB and plasma, although the inhibitory effect of thrombomodulin was drastically weaker in WB than in plasma. The peak of WB‐TG in patients correlated moderately with their hematocrit and platelet count. Significant correlations were found between TG results in WB and plasma. Conclusions The WB‐TG assay shows a normal to hypocoagulable state in patients with cirrhosis with a decreased anticoagulant activity of TM compared to plasma‐TG. The clinical value of this assay needs further validation.
2 November 2023 in Blood Advances
Red blood cells (RBCs) and platelets contribute to the coagulation capacity in bleeding and thrombotic disorders. The thrombin generation (TG) process is considered to reflect the interactions between plasma coagulation and the various blood cells. Using a new high-throughput method capturing the complete TG curve, we were able to compare TG in whole blood and autologous platelet-rich and platelet-poor plasma to redefine the blood cell contributions to the clotting process. We report a faster and initially higher generation of thrombin and shorter coagulation time in whole blood than in platelet-rich plasma upon low concentrations of coagulant triggers, including tissue factor, Russell viper venom factor X, factor Xa, factor XIa, and thrombin. The TG was accelerated with increased hematocrit and delayed after prior treatment of RBC with phosphatidylserine-blocking annexin A5. RBC treatment with ionomycin increased phosphatidylserine exposure, confirmed by flow cytometry, and increased the TG process. In reconstituted blood samples, the prior selective blockage of phosphatidylserine on RBC with annexin A5 enhanced glycoprotein VI–induced platelet procoagulant activity. For patients with anemia or erythrocytosis, cluster analysis revealed high or low whole-blood TG profiles in specific cases of anemia. The TG profiles lowered upon annexin A5 addition in the presence of RBCs and thus were determined by the extent of phosphatidylserine exposure of blood cells. Profiles for patients with polycythemia vera undergoing treatment were similar to that of control subjects. We concluded that RBC and platelets, in a phosphatidylserine-dependent way, contribute to the TG process. Determination of the whole-blood hypo- or hyper-coagulant activity may help to characterize a bleeding or thrombosis risk.
28 February 2020 in Journal of Thrombosis and Haemostasis
Background Fluorogenic thrombin generation (TG) assays are commonly used to determine global coagulation phenotype in plasma. Whole blood (WB)‐TG assays reach one step closer to physiology by involving the intrinsic blood cells but erythrocytes cause variable quenching of the fluorescence signals, hampering its routine application. Objective To develop a new assay for continuous WB‐TG measurement. Methods In the new WB‐TG assay, the erythrocyte‐caused distortion of signal was solved by continuously mixing the sample during the measurement. The assay was validated by evaluating the reproducibility and comparing with the paper‐based WB‐TG assay (Ninivaggi et al., 2012). Reconstituted human blood and WB from 119 healthy donors was tested to explore the influences of hematocrit and platelet count on TG. Results This novel WB‐TG assay showed good reproducibility, while being less affected by contact activation compared with the previous paper‐based assay. Reconstitution experiments showed that the Lagtime of TG was shortened by the addition of platelets but not erythrocytes. Increasing hematocrit strongly augmented the Peak thrombin, even in the presence of high platelet counts. The Lagtime and Peak of WB‐TG of 119 healthy donors were positively related to erythrocyte count after adjusting for age, sex and oral contraceptive use with multiple linear regression analyses. The reference range and inter‐individual variation of WB‐TG were determined in the healthy cohort. Conclusions A novel WB‐TG assay was developed, which is a straight forward tool to measure the involvement of platelets and erythrocytes in TG and may assist the research of blood cells‐associated coagulation disorders.